The control of blood pressure worldwide is disappointing; hence, the Lancet Commission on
Arterial Hypertension identified the 9 key actions to combat this major risk factor and, for the …

We welcome the letter by Tanemoto et al.[1] for giving us an opportunity to discuss and
update our results concerning the study of adrenocorticotrophic hormone (ACTH)-testing …

Primary aldosteronism (PA) is the most common cause of secondary hypertension. 1 It is
well established that patients with this clinical syndrome have greater target organ damage …

Primary aldosteronism (PA) has a prevalence in the general hypertensive population from 5
to 10%, and is widely recognized as the most frequent form of secondary hypertension. The …

Numerous studies conducted in recent years have reported an increase in the prevalence of
primary aldosteronism (PA). This increase has arisen because of changes in our screening …

Primary aldosteronism (PAL) is gaining recognition as an important cause of hypertension,
and attention is focusing more critically on the reliability of screening tests for PAL. However …

Arterial hypertension is a major public health problem that affects more than 1 billion
patients worldwide, a number that is expected to rise to 1.5 billion1 because of aging of the …

Arterial hypertension is a major risk factor for cardiovascular disease. The prevalence of
primary aldosteronism (PA) ranges from 5% to 10% in the general hypertensive population …

Primary aldosteronism is the most common endocrine cause of hypertension, and is often
associated with treatment-resistant hypertension. 1 It is characterized by autonomous …

Several studies over the past 3 decades document a higher prevalence of primary
aldosteronism (PA) among hypertensive patients than generally presumed. PA exists as a …